News

Friday, 24 July 2020

Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options


News published by Insmed Incorporated concerning ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, administered with Lamira®, an optimised eFlow® Technology nebuliser.

Read more


Tuesday, 7 July 2020

New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease


News published by Insmed Incorporated concerning ARIKAYCE® (amikacin liposome inhalation suspension), administered with Lamira®, an optimised eFlow® Technology nebuliser.

Read more


Thursday, 18 June 2020

Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases


News published by Renovion, Inc., concerning their lead therapeutic candidate ARINA-1 administered via an optimised eFlow® Technology nebuliser.

Read more


Monday, 01 June 2020

Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference


News published by Biomarck Pharmaceuticals concerning its novel anti-MARCKS peptide BIO-11006 in non-small cell lung cancer (NSCLC) administered via an optimised eFlow® Technology nebuliser.

Read more


Tuesday, 28 April 2020

A new FDA Fast Track designation for Zambon

The designation is for L‑CsA‑i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a Zambon company.


News published by Zambon concerning L-CsA-i, administered via an optimised investigational eFlow® Technology nebuliser.

Read more


Thursday, 20 February 2020

Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)


News published by Breath Therapeutics concerning L-CsA-i, administered via an optimised investigational eFlow® Technology nebuliser.

Read more


Monday, 16 December 2019

Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency


News published by Kamada Ltd. concerning Inhaled AAT, administered via an optimised investigational eFlow® Technology nebuliser.

Read more


Tuesday, 10 September 2019

Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis


News published by Santhera Pharmaceuticals concerning POL6014 in cystic fibrosis, administered with an optimised investigational eFlow® Technology nebuliser.

Read more


Thursday, 25 July 2019

PARI Pharma spin-out Breath Therapeutics acquired by Zambon Pharma


News published by Zambon Pharma concerning the acquisition of biopharmaceutical company Breath Therapeutics

Read more

News published by Gimv concerning the sale of biopharmaceutical company Breath Therapeutics

Read more

News published by Sofinnova Partners concerning the sale of biopharmaceutical company Breath Therapeutics

Read more


Monday, 20 May 2019

Respivant Sciences Announces Dosing of First Patient in Phase 2b Trial of RVT-1601 for the Treatment of Persistent Cough Due to Idiopathic Pulmonary Fibrosis


News published by Respivant Sciences concerning RVT-1601, administered with an optimized investigational eFlow® Technology nebuliser.

Read more


Monday, 20 May 2019

New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease


News published by Insmed Incorporated concerning ARIKAYCE® (amikacin liposome inhalation suspension), administered with Lamira®, an optimised eFlow® Technology nebuliser.

Read more


Thursday, 08 May 2019

Investigating GM-CSF in aPAP: A Logical Replacement of a Dysfunctional Protein


News published by Savara Pharmaceuticals concerning Molgradex (GM-CSF) in aPAP, administered with an optimized investigational eFlow® Technology nebuliser.

Read more


Wednesday, 01 May 2019

Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019


News published by Sunovion Pharmaceuticals Inc. presenting data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019.

Read more


Tuesday, 26 March 2019

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.


News published by Breath Therapeutics concerning L-CsA-I, administered via an optimized investigational eFlow® Technology nebuliser.

Read more


Tuesday, 02 October 2018

PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).


ARIKAYCE® is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options

Read more


Thursday, 07 December 2017

MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)


LONHALA MAGNAIR Inhalation Solution is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S.

Read more

Contact us

Do you have any questions about our technology, partnering approach and services?

Please contact us!
eFlow-partneringpari.com